VYEPTI (EPTINEZUMAB-JJMR)

Infusion Orders

INFUSION	CARE		PHO	NE 515.225.2930	FAX 515.559.2495		
Patient Informa	tion	Fax completed form, ins	urance information	on and clinical documer	ntation to 515.559.2495.		
Patient Name:			DOB:	Phone:			
Patient Status:	New to Therapy	Continuing Therapy	Next Treatme	nt Date:			
Medical Informa	ation						
Diagnosis: C	hronic migraines Episo	dic migraines Other:					
ICD-10 Code:							
Patient Weight: Ibs. (required) Allergies:							
Therapy Order							
Vyepti 100 mg IV eve 300 mg IV eve	-						
Refill for: 6	months lyear Othe	er:					
Other orders:							
Lab Orders:		Frequency:	Every infusio	on Other:			
Required labs to be drawn by: Hy-Vee Health Referring Provider							
 Anaphylactic reaction orders: Epinephrine (based on patient weight) >30kg (>66lbs): EpiPen 0.3 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1 15-30kg (33-66lbs): EpiPen Jr. 0.15 mg or compounded syringe IM or Sub-Q; may repeat in 5-10 minutes x1 Diphenhydramine: Administer 25-50 mg orally OR IV (adult) Refer to physician order or institutional protocol for pediatric dosing Flush orders: NS 1-20 mL pre/post infusion PRN and Heparin 10U/mL or 100U/mL per protocol as indicated PRN 							
Provider Inform	ation						
	m and utilizing our services, yc y designated agent in dealing						
Provider Name:		Signature:		Da	ate:		
Provider NPI:	Phone:	Fax:		Contact Person:			
Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care):							
Service Areas							

Scivice Areas					
Des Moines, IA	West Des Moines, IA	Chicago, IL	Omaha, NE	Buffalo, NY	Dallas, TX
Phoenix, AZ	Other				

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.

Hyvee health.



COMPREHENSIVE SUPPORT FOR VYEPTI THERAPY

Patient Information

Patient Name:	DOB:						
Required Documentation for Referral Processing & Insurance Approval							
Include <u>signed</u> and <u>completed</u> order (ME	Include <u>signed</u> and <u>completed</u> order (MD/prescriber to complete page 1)						
Include patient demographic information	n and insurance information						
Include patient's current medication list							
Supporting clinical notes to include any p to conventional therapy	past tried and/or failed therapies, intolerance, benefits or contraindications						
Has the patient had a documented co Yes No	ntraindication/intolerance or failed trial ofprophylactic migraine therapy?						
If yes, which drug(s): Amitriptyline Beta blocker Divalproex Topiramate Venlafaxine Other:							
Has the patient had a documented co receptor? If yes, please indicate drug:	ntraindication/intolerance or failed trial of a calcitonin gene-related peptide						
Aimovig Emgality Ajovy C	Dther:						
	ve greater than or equal to 15 headache days/month; OR greater than or equal to No						
If yes, how many?							
Episodic migraine: does the patient ha days per month? Yes No	ive less than 15 headache days per month; OR patient has 4-14 migraine						
If yes, how many?							
Include labs and/or test results to suppor	t diagnosis (if applicable)						
Other medical necessity:							

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.